Axon Enterprise, Inc. (NASDAQ:AXON) Shares Acquired by Castleark Management LLC

Castleark Management LLC grew its stake in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 317.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 11,570 shares of the biotechnology company's stock after buying an additional 8,800 shares during the quarter. Castleark Management LLC's holdings in Axon Enterprise were worth $6,876,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in AXON. New Wave Wealth Advisors LLC purchased a new position in shares of Axon Enterprise in the 4th quarter valued at about $40,000. Y.D. More Investments Ltd purchased a new position in shares of Axon Enterprise in the 4th quarter valued at about $45,000. Elequin Capital LP purchased a new position in shares of Axon Enterprise in the 4th quarter valued at about $46,000. Stonebridge Financial Group LLC purchased a new position in shares of Axon Enterprise in the 4th quarter valued at about $53,000. Finally, GPS Wealth Strategies Group LLC boosted its stake in shares of Axon Enterprise by 74.1% in the 4th quarter. GPS Wealth Strategies Group LLC now owns 94 shares of the biotechnology company's stock valued at $56,000 after buying an additional 40 shares during the period. Hedge funds and other institutional investors own 79.08% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Needham & Company LLC lifted their price objective on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Barclays lifted their price objective on Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. JMP Securities restated an "outperform" rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. Craig Hallum cut Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. Finally, The Goldman Sachs Group boosted their target price on Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, Axon Enterprise presently has an average rating of "Moderate Buy" and a consensus target price of $652.73.

Axon Enterprise Stock Performance

AXON traded up $7.62 during trading on Friday, hitting $731.37. 422,330 shares of the stock were exchanged, compared to its average volume of 743,966. The firm has a market capitalization of $56.94 billion, a P/E ratio of 188.98, a PEG ratio of 5.17 and a beta of 1.24. Axon Enterprise, Inc. has a 1-year low of $273.52 and a 1-year high of $748.80. The stock has a fifty day moving average price of $603.25 and a two-hundred day moving average price of $603.88. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.34 by $0.07. The company had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The firm's revenue was up 31.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.15 earnings per share. As a group, sell-side analysts predict that Axon Enterprise, Inc. will post 5.8 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Patrick W. Smith sold 10,000 shares of the business's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $540.99, for a total value of $5,409,900.00. Following the transaction, the chief executive officer now owns 3,063,982 shares of the company's stock, valued at approximately $1,657,583,622.18. The trade was a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, President Joshua Isner sold 9,905 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $738.03, for a total value of $7,310,187.15. Following the completion of the transaction, the president now directly owns 298,809 shares in the company, valued at approximately $220,530,006.27. The trade was a 3.21% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,969 shares of company stock valued at $23,127,314 over the last quarter. Company insiders own 4.40% of the company's stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.